Status:
COMPLETED
Evaluation in Practice of the Impact of NIrsevimab on EmeRgency Use for BRONCHIOlitis
Lead Sponsor:
Hôpital Armand Trousseau
Conditions:
Bronchiolitis
Respiratory Syncytial Virus (RSV)
Eligibility:
All Genders
1-2 years
Brief Summary
In July 2023, the Food and Drug Administration approved nirsevimab (Beyfortus®), a long-acting monoclonal antibody, for passive immunization to prevent RSV-associated lower respiratory tract infection...
Detailed Description
Bronchiolitis is a very common viral lower respiratory tract infection in infants that consists of swelling of the small airway passages in the lungs. Signs and symptoms typically begin with rhinitis ...
Eligibility Criteria
Inclusion
- All infants aged 1 year or youger visiting the emergecy department
- All bronchiolitis visiting the emergency department during the 2023-2024 season
Exclusion
- None
Key Trial Info
Start Date :
October 14 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 29 2024
Estimated Enrollment :
4924 Patients enrolled
Trial Details
Trial ID
NCT06185647
Start Date
October 14 2023
End Date
February 29 2024
Last Update
July 30 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Armand Trousseau
Paris, France, 75012